CAR T Cell Therapy Market 2018-2028 - Global Forecast by Regions, Targeted Antigens, Clinical Trials/Study, Companies - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Aug 23, 2018--The “CAR T Cell Therapy Market Global Forecast by Regions, Targeted Antigens, Clinical Trials/Study, Companies, and Celgene Corporation” company profile has been added to ResearchAndMarkets.com’s offering.
CAR T Cell therapy market is expected to grow with a CAGR of over 46% in the forecast period
Year 2017 has created new milestone for the oncology patients as FDA approved the first two CD19-targeted (Chimeric Antigen Receptor) CAR T cell therapies developed by Novartis and Gilead Sciences/Kite Pharma in the United States. These two approvals will certainly help to boost the global CAR T cell therapy market as more players are looking for big opportunities to enter the market place. At present over 200 CAR T clinical trials are running or completed across various parts of the world.
Rising numbers of adults and children developing cancer, increasing government initiatives for promoting research for cell therapy in cancer and rising number of clinical trials globally are some of the key drivers for the global CAR T Cell therapy market; however high cost of CAR T cell therapy treatment and regulatory challenges are key inhibitors for this market.
This report studies the Global CAR T cell therapy market from 2 key view points by CAR T cell therapy market and CAR T cell therapy studies. Market segments are further studied by geographical regions and targeted antigens whereas CAR T cell therapy studies by targeted antigens globally and China specific. The report provides a complete analysis of the key Growth Drivers and Challenges, SWOT analysis, market, and their projections for the upcoming years (2028).
The report has been analyzed from 9 major viewpoints
1. Targeted Antigen - Global CAR T Cell Therapy Market
2. Regional CAR T Cell Therapy Market
3. Global - CAR T Cell Therapy Clinical Trials/Study
4. China CAR T Cells Clinical Trials Details
5. CAR T Cell Therapy SWOT Analysis
6. The Regulation in CAR T Cell Therapy
7. Global - IPO/Investment/Funding/Partnership in CAR T Cell Therapy Market
8. Growth Drivers and Challenges
9. Key CAR T companies Initiatives and Financial Insight
Targeted Antigens - Global CAR T Cell Therapy Market & ForecastCD19 CD20 GD2 CD22 CD30 CD33 HER2 MESO EGFRvII Others
Regional CAR-T Cell Therapy Market & ForecastNorth America Europe Asia Pacific Latin America Middle East Africa
Global - CAR T Cell Therapy Clinical Trials/StudyCD19 CD20 GD2 CD22 CD30 CD33 HER1 HER2 MESO EGFRvII
China CAR T Cells Clinical Trials DetailsBy Cities CAR T Cells Clinical Trials CD19 Directed CAR T Cells Clinical Trials Non-CD19 Directed CAR T Cells Clinical Trials Solid Tumors CAR T Cells Clinical Trials
The Regulation in CAR T Cell TherapyUnited States European Union China
IPO/Investment/Funding/Partnership in CAR T Cell Therapy MarketVenture Capital Investment Initial Public Offerings Strategic Partnerships/Deals Key CAR T Technology Deals
Key Companies covered in this report areNovartis Gilead Sciences (Kite Pharma) Celgene Corporation (Juno Therapeutics) Celyad
For more information about this company profile visit https://www.researchandmarkets.com/research/372757/car_t_cell?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180823005457/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Company Reports
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY ONCOLOGY
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 08/23/2018 09:36 AM/DISC: 08/23/2018 09:36 AM